Noevir Announces 2025 Consolidated Results

November 7, 2025

Trade name: Noevir Holdings Co., Ltd.

Listing: Tokyo Stock Exchange, Prime Market (Securities Code: 4928) URL: https://www.noevirholdings.co.jp/

Representative: Takashi Okura, President and CEO Contact: Junya Baba, General Manager, Accounting

Tel. +81-78-303-5121

Annual General Meeting of Shareholders: December 9, 2025 Date of commencement of dividend payments: December 10, 2025 Submission of securities report: December 8, 2025

Supplemental materials for the financial results prepared: Yes

Results briefing for the reporting period held: Yes (for institutional investors and analysts)

(Amounts under one million yen have been rounded down)

1. Operating results for the fiscal year ended September 30, 2025 (October 1, 2024 to September 30, 2025)

   1. Consolidated operating results

      (Millions of yen; percentage figures denote year-on-year change)

      	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent
      Fiscal year ended September 30, 2025	64,724	1.4 %	11,075	(3.0) %	11,774	1.6 %	8,030	0.8 %
      Fiscal year ended September 30, 2024	63,823	2.0 %	11,423	3.6 %	11,594	2.6 %	7,970	3.9 %

      Note: Comprehensive income:

      Fiscal year ended September 30, 2025: 8,142 million yen [(2.1)%]

      Fiscal year ended September 30, 2024: 8,319 million yen [1.2%]

      	EPS (Yen)	Diluted EPS (Yen)	ROE (%)	Ordinary income/ Total assets (%)	Operating income/ Total sales (%)
      Fiscal year ended September 30, 2025	235.10	-	15.0	15.4	17.1
      Fiscal year ended September 30, 2024	233.34	-	15.0	15.1	17.9

      [Reference]

      Equity in gain/losses of affiliated companies

      Fiscal year ended September 30, 2025: - million yen Fiscal year ended September 30, 2024: - million yen

   2. Consolidated financial position

      (Millions of yen)

      	Total assets	Net assets	Equity ratio (%)	Net assets per share (Yen)
      As of September 30, 2025	76,492	54,209	70.3	1,574.17
      As of September 30, 2024	76,471	53,906	69.9	1,565.68

      [Reference] Equity:

      As of September 30, 2025: 53,767 million yen

      As of September 30, 2024: 53,477 million yen

   3. Consolidated cash flows

   (Millions of yen)

   	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents, end of year
   Fiscal year ended September 30, 2025	7,928	(2,417)	(7,924)	26,723
   Fiscal year ended September 30, 2024	9,123	1,525	(7,712)	29,006

2. Cash dividends

   	Annual dividends (Yen)					Total dividend amount (Millions of yen) (Annual)	Payout ratio (%) (Consolidated)	Dividends/ Shareholders' equity (%) (Consolidated)
   	1st quarter	2nd quarter	3rd quarter	Year-end	Total
   Fiscal year ended September 30, 2024	-	0.00	-	225.00	225.00	7,685	96.4	14.5
   Fiscal year ended September 30, 2025	-	0.00	-	230.00	230.00	7,855	97.8	14.7
   Fiscal year ending September 30, 2026 (forecast)	-	0.00	-	230.00	230.00		95.8

3. Consolidated earnings forecasts for the fiscal year ending September 30, 2026 (October 1, 2025 to September 30, 2026)

(Millions of yen; percentage figures denote year-on-year change)

* Notes

1. Significant changes in the scope of consolidation during the period: None

2. Changes in accounting policies, changes in accounting estimates, and restatement

   1. Changes associated with revision in accounting standards: Yes

   2. Other changes: None

   3. Changes in accounting estimates: None

   4. Restatement: None

3. Shares outstanding (common stock)

   1. Shares outstanding (including treasury stock) As of September 30, 2025: 34,156,623

      As of September 30, 2024: 34,156,623

   2. Treasury shares outstanding

      As of September 30, 2025: 416

      As of September 30, 2024: 416

   3. Average shares outstanding over quarter

Fiscal year ended September 30, 2025: 34,156,207

Fiscal year ended September 30, 2024: 34,156,316

Note: Please refer to "Note on per-share information" on page 20 of the Attached Material regarding the formula used to calculate earnings per share (consolidated).

• Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

• Explanation regarding the appropriate use of business performance forecasts

  Forward-looking statements included in these materials, such as forecasts of business performance, are based on information known to the Company's management as of the time of writing, and reflect judgments believed to be reasonable on the basis of that information. There is, therefore, a possibility that actual business performance figures will differ substantially from our forecasts as a result of changes in the economic situation and other unforeseeable factors. Please refer to "(1) Operating results for the fiscal year ended September 30, 2025" under "1. Operating results and financial information" on page 4 of Attached Material.

  Contents of the Attached Material

  1. Operating results and financial information 4

     1. Operating results for the fiscal year ended September 30, 2025 4

     2. Financial position as of September 30, 2025 6

     3. Profit distribution/dividend payment for the reporting term and the current term 6

  2. Management strategy 7

     1. Basic management policies and medium- to long-term strategy 7

     2. Numerical targets and achievements 7

     3. Key issues 7

  3. Basic Approach to Selecting Accounting Principles 7

  4. Consolidated financial statements and notes 8

     1. Consolidated balance sheets 8

     2. Consolidated statements of income and comprehensive income 10

     3. Consolidated changes to equity 12

     4. Consolidated statements of cash flows 14

     5. Notes to consolidated financial statements 15

(Note on assumptions for going concern) 15

(Note on changes in accounting policies) 15

(Note on change in presentation method) 15

(Note on consolidated balance sheets) 15

(Note on segment information, etc.) 16

(Note on per-share information) 20

(Note on important subsequent events) 20

1. ‌Operating results and financial information‌

   1. Operating results for the fiscal year ended September 30, 2025

1. Consolidated operating results for the reporting fiscal period

   < >

   	Fiscal year ended September 30, 2024		Fiscal year ended September 30, 2025		Change (Millions of yen)	Change (%)
   	Net sales (Millions of yen)	% of Total	Net sales (Millions of yen)	% of Total
   Net sales	63,823	100.0	64,724	100.0	901	1.4
   Cosmetics	49,761	78.0	50,525	78.1	763	1.5
   Pharmaceuticals & Health Food	11,443	17.9	11,535	17.8	91	0.8
   Other	2,618	4.1	2,664	4.1	46	1.8

   	Fiscal year ended September 30, 2024		Fiscal year ended September 30, 2025		Change (Millions of yen)	Change (%)
   	Amount (Millions of yen)	% of Net sales	Amount (Millions of yen)	% of Net sales
   Operating income	11,423	17.9	11,075	17.1	(347)	(3.0)
   Ordinary income	11,594	18.2	11,774	18.2	179	1.6
   Net income attributable to owners of the parent	7,970	12.5	8,030	12.4	60	0.8

   During fiscal 2025 (October 1, 2024 to September 30, 2025), economic trends remained uncertain, although some signs of gradual recovery were observed.

   In this environment, the Company is working to realize the concept of its medium- to long-term strategy: "Realizing steady corporate growth by securing sustainability in every Group business segment."

   As a result, net sales for the fiscal year ended September 30, 2025 came to 64,724 million yen (up 1.4% year on year), operating income was 11,075 million yen (down 3.0%), ordinary income was 11,774 million yen (up 1.6%), and net income attributable to owners of the parent came to 8,030 million yen (up 0.8%). Notably, net income attributable to owners of the parent was a record high.

   <>

   1. Cosmetics

      (Millions of yen)

      	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025	Change (Millions of yen)	Change (%)
      Net sales	49,761	50,525	763	1.5
      Segment income	12,226	12,292	66	0.5

      Sales in the Cosmetics segment totaled 50,525 million yen (up 1.5% year on year), and segment income came to 12,292 million yen (up 0.5%).

   2. Pharmaceuticals & Health Food

      (Millions of yen)

      	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025	Change (Millions of yen)	Change (%)
      Net sales	11,443	11,535	91	0.8
      Segment income	1,230	980	(250)	(20.4)

      Sales in the Pharmaceuticals & Health Food segment totaled 11,535 million yen (up 0.8% year on year), and segment income came to 980 million yen (down 20.4%).

   3. Other

      (Millions of yen)

      	Fiscal year ended September 30, 2024	Fiscal year ended September 30, 2025	Change (Millions of yen)	Change (%)
      Net sales	2,618	2,664	46	1.8
      Segment income	330	301	(29)	(8.9)

      Sales in the Other segment came to 2,664 million yen (up 1.8% year on year), and segment income came to 301 million yen (down 8.9%).

2. Forecast for the current fiscal year ending September 30, 2026

Although a gradual economic recovery is anticipated, the outlook is expected to remain uncertain due to factors such as the risk of downward pressure on consumer spending caused by rising prices.

In this environment, the Company will move forward aiming to realize the concept of its medium- to longterm strategy: "Realizing steady corporate growth by securing sustainability in every Group business segment." With this aim in mind, the Company's consolidated forecast for the fiscal year ending September 30, 2026 is for net sales of 65,000 million yen, operating income of 11,400 million yen, ordinary income of 11,800 million yen, and net income attributable to owners of the parent of 8,200 million yen.